Kunter, E.Çermik, H.Işıtmangil, T.Kandemir, E. G.Yaylacı, MustafaÖztürk, A.2024-07-122024-07-122003Türken O, Kunter E, Çermik H, Işıtmangil T, Kandemir EG, Yaylacı M, Öztürk A. Prevalance and prognostic value of c-erbB2 expression in non-small cell lung cancer (NSCLC). Neoplasma, AEPress. 50, s. 257-261.0028-26851338-4317http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=675&category_id=31&option=com_virtuemart&vmcchk=1&Itemid=1https://hdl.handle.net/20.500.12415/4242The c-erbB2 oncoprotein is highly expressed in approximately one third of non-small cell lung cancer (NSCLC) patients. We determined the status of c-erbB2 expression in our patients with NSCLC and investigated its correlation with disease stage, histological type and response to treatment. Eighty-four patients were examined for the expression of c-erbB2 by immunohistochemistry using a polyclonal antibody. The scoring criteria of Clinical Trial Assay (CTA) were used to evaluate staining (0 to +3). c-erbB2 overexpression was determined in 35% of the cases. Tumors from higher stage disease (stage IIIb-IV) were more often c-erbB2 positive in adenocarcinoma (ADC) (p=0.04). In addition, there was an association between c-erbB2 score and disease stage in ADC patients (p=0.03). Our study did not demonstrate an association of c-erbB2 overexpression with response to chemotherapy. We conclude that c-erbB2 overexpression may be a prognostic marker for evaluating tumor progression in NSCLC patients but further studies must be performed with larger patient populations.enCC0 1.0 Universalinfo:eu-repo/semantics/openAccessNon-smalllungcancerc-erbB2Article261Q225750